ALB and neoplasm: The introduction of albumin-binding moiety to small-molecule therapeutics has indeed been investigated as a strategy to enhance therapeutic efficacy by extending circulation half-life and improving tumor uptake, as small-molecule therapeutics experience short tumor retention times [66].